Stephens Investment Management Group LLC grew its stake in Simulations Plus, Inc. (NASDAQ:SLP – Free Report) by 30.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 513,728 shares of the technology company’s stock after buying an additional 120,888 shares during the period. Stephens Investment Management Group LLC owned 2.55% of Simulations Plus worth $9,365,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of SLP. Royal Bank of Canada increased its position in shares of Simulations Plus by 26.6% during the first quarter. Royal Bank of Canada now owns 114,885 shares of the technology company’s stock worth $2,817,000 after purchasing an additional 24,132 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Simulations Plus by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock valued at $233,000 after purchasing an additional 390 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Simulations Plus during the 1st quarter worth $255,000. Woodline Partners LP increased its stake in Simulations Plus by 32.1% in the first quarter. Woodline Partners LP now owns 13,239 shares of the technology company’s stock valued at $325,000 after purchasing an additional 3,220 shares during the period. Finally, Rhumbline Advisers increased its stake in Simulations Plus by 12.2% in the second quarter. Rhumbline Advisers now owns 74,325 shares of the technology company’s stock valued at $1,297,000 after purchasing an additional 8,103 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on SLP shares. Zacks Research downgraded shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. TD Cowen reduced their price objective on Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, April 10th. Finally, Wall Street Zen upgraded Simulations Plus from a “hold” rating to a “buy” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Simulations Plus presently has a consensus rating of “Hold” and an average price target of $24.40.
Simulations Plus Price Performance
NASDAQ SLP opened at $13.34 on Monday. The stock has a market capitalization of $269.47 million, a P/E ratio of -4.26 and a beta of 1.28. Simulations Plus, Inc. has a 52-week low of $11.09 and a 52-week high of $34.01. The firm has a 50-day moving average price of $13.23 and a 200 day moving average price of $15.75.
Simulations Plus (NASDAQ:SLP – Get Free Report) last announced its quarterly earnings data on Thursday, April 9th. The technology company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.08. Simulations Plus had a positive return on equity of 16.21% and a negative net margin of 77.96%.The company had revenue of $24.29 million for the quarter, compared to analyst estimates of $21.66 million. On average, equities research analysts expect that Simulations Plus, Inc. will post 0.85 earnings per share for the current fiscal year.
Simulations Plus Company Profile
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
Read More
- Five stocks we like better than Simulations Plus
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
